AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for SLAM family member 6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96DU3

UPID:

SLAF6_HUMAN

Alternative names:

Activating NK receptor; NK-T-B-antigen

Alternative UPACC:

Q96DU3; A6NMW2; B2R8X8; Q14CF0; Q5TAS4; Q5TAS6; Q5TAT3; Q96DV0

Background:

SLAM family member 6, also known as Activating NK receptor or NK-T-B-antigen, plays a pivotal role in immune regulation. It modulates the activation and differentiation of various immune cells, contributing to both innate and adaptive immune responses. This protein's function is influenced by the presence of adapter proteins SH2D1A/SAP and SH2D1B/EAT-2, which control its signaling pathways. It is particularly crucial in natural killer (NK) cell activation, T-cell differentiation into Th17 phenotype, and the regulation of germinal center formation.

Therapeutic significance:

Understanding the role of SLAM family member 6 could open doors to potential therapeutic strategies. Its involvement in key immune processes suggests its potential as a target in modulating immune responses, offering avenues for the development of treatments for immune-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.